People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.

People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.

Scientists found altered activity of the PUM1 protein plays a key role in pulmonary hypertension development, making it a PH ...

Tiakis Biotech is preparing for a Phase 2 U.S. trial of tiprelestat for PAH after completing a data package required for ...

This holiday season, columnist Anna Jeter is searching for some silver linings in her life and to try to be grateful, despite ...

A mouse study shows overproduction of the naturally occurring hormone adrenomedullin reduced lung injury and PH in ...

Scientists identified two proteins as biomarkers of CTEPH severity and progression, a discovery that could pave the way for future treatment.

The World Health Organization (WHO) classifies pulmonary hypertension (PH), a progressive lung disease, into five main groups according to its underlying cause. All types of PH are characterized by ...

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

Pulmonary hypertension is a rare lung disease characterized by increased blood pressure in the pulmonary arteries that eventually makes breathing very difficult. Breathing is the most important thing ...

Pulmonary hypertension (PH) is a rare but life-threatening lung disorder that damages the vessels responsible for transporting blood from the heart to the lungs, known as the pulmonary arteries. The ...

What is Opsumit for pulmonary arterial hypertension? Opsumit (macitentan) is an oral medication approved to reduce the risk of disease progression and hospitalization in adults with pulmonary arterial ...